Relyvrio, a drug approved to treat ALS, did not improve patients' physical functions, quality of life, respiratory function, or overall survival in a recent clinical trial involving 664 patients.
Despite shaky data, the FDA initially granted approval for Relyvrio based on a study of 137 patients, highlighting the need for more effective treatments for ALS.
Amylyx, the company behind Relyvrio, is laying off 70% of its workforce and pulling the drug from the market following the failed clinical trial results.
[
add
]
[
|
|
...
]